Short answer
Kura Oncology, Inc. (KURA) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $21M with net income of −$74M.
Q3 2025 key financials · XBRL
- Revenue
- $21M
- +35.7% QoQ
- Net income
- −$74M
- −36.2% YoY · −12.1% QoQ
- Operating margin
- -385.5%
- EPS (diluted)
- −$0.85
- −37.1% YoY · −13.3% QoQ
Source: XBRL data from the Kura Oncology, Inc. (KURA) Q3 2025 10-Q on SEC EDGAR. USD.
Kura Oncology, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New NDA-review risk: FDA accepted ziftomenib’s AML NDA in Q2 2025, but may issue a complete response letter
- Regulatory safety risk: FDA adjudicated two fatal cases where differentiation syndrome could not be ruled out
- Clinical-development risk: Ziftomenib treatment-related differentiation syndrome occurred in more than 10% of patients
- Diagnostic-compliance risk: Expected ziftomenib approval includes a post-marketing commitment for an NPM1 companion diagnostic study
- Commercial concentration risk: Business depends entirely on successfully developing and commercializing ziftomenib
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kura Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.